Therapeutic Response Statement (Sensitivity) Deprecated

This therapeutic response statement Supports the relationship that CD20 + status confers therapeutic sensitivity to Carboplatin, Etoposide, Ifosfamide, Rituximab in patients with Non-Hodgkin Lymphoma.

The Republic of Ireland's Health Service Executive (HSE) has approved carboplatin in combination with ifosfamide and etoposide (ICE) for reimbursement as a treatment option for the treatment of relapsed/refractory Non Hodgkin's Lymphoma. The therapy regimen further states that rituximab is to be included for the treatment of CD20 positive patients.

This statement is based on a regulatory approval from the Health Service Executive:

Treatment of relapsed / refractory Non Hodgkin's Lymphoma. Rituximab to be included in CD20 positive patients.

Citation

(R*)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy, 2022, version number 4a, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6372/397_R-ICE.pdf

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2017-07-08	Health Service Executive	Indication approved for reimbursement.